DV
Dividend Vision

ALT — Altimmune, Inc.

Altimmune, Inc. (ALT)

Its deepest 1-year drawdown was 58.1%.

This appears to be a single-stock listing rather than a diversified ETF. Altimmune, Inc. is a biotechnology company with no reported dividend distribution rate or yield profile. The equity holding offers exposure to a clinical-stage biotech firm focused on immunotherapy development, making it suited for investors seeking growth potential rather than income generation.

ALT key facts

Asset type
Stock
Asset class
Equity
Inception date
10/06/2005
Last close
$2.94
Market cap
$571,882,048
Average volume
3022700.0
Ex-dividend date
01/20/2017
Payment date
09/14/2018
Beta
0.169
Payout ratio
0.0
Forward P/E
8.1766
EPS
$-0.78